Various albumin-based formulations are in the clinical trial phase such as MTX-HSA, Aldoxorubicin, CJC-1134, Abraxane®, and ABI-008, 99mTc-Albures (Larsen et al., 2016; Bayat Mokhtari et al., 2018), and a few are already approved by the FDA, such as Abraxane, i.e., paclitaxel–albumin nanoparticles, for the treatment of advanced non-small-cell lung cancer and metastatic breast cancer (Gradishar et al., 2005). This evidence concerns the gene ALB and non-small cell lung carcinoma.